An international panel of experts in conjunction with the Consortium of MS Centers (CMSC) has developed recommendations on the use of neurofilament-light chain (NfL) as a biomarker of disease activity in multiple sclerosis (Freedman et al. eBioMedicine 2024;101:104970). Read More
Latest News
New developments in epilepsy: focus on cenobamate
May 2, 2024Cenobamate received Health Canada authorization last year as adjunctive therapy for patients with partial-onset seizures who are not adequately controlled with conventional therapies. The drug acts as a sodium channel blocker through selection inhibition of the persistent sodium current, and as a GABAA receptor modulator. Read More
Treatment initiation with a higher-efficacy DMT: update from AAN
April 25, 2024Focus on ofatumumab
There is a growing body of evidence supporting the use of high-efficacy disease-modifying therapies (DMT) as first-line agents in the treatment of multiple sclerosis. Since the TRANSFORMS trial over a decade ago, numerous pivotal trials have demonstrated the superiority of higher-efficacy DMTs over lower-efficacy agents (Cohen et al. N Engl J Med 2010;362:402-415). The concern with this more aggressive approach was safety. However, the accumulation of long-term safety data, most notably for anti-CD20 agents, has demonstrated the low risk of serious adverse events with sustained exposure to selected high-efficacy DMTs in clinical practice. Read More
REPORT FROM AAN 2024 – THURSDAY, APRIL 18
April 18, 2024American Academy of Neurology annual meeting – 13-18 April 2024
The following summarizes some of the highlights from Day 4 of AAN 2024.